Russell Schundler Sells 13,692 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 13,692 shares of the company’s stock in a transaction on Monday, April 13th. The stock was sold at an average price of $38.37, for a total transaction of $525,362.04. Following the completion of the sale, the general counsel owned 610,532 shares of the company’s stock, valued at approximately $23,426,112.84. The trade was a 2.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Down 0.4%

Shares of LQDA traded down $0.14 during trading hours on Tuesday, reaching $38.71. 844,813 shares of the stock traded hands, compared to its average volume of 1,775,539. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $46.67. The company has a market cap of $3.41 billion, a price-to-earnings ratio of -46.64 and a beta of 0.45. The stock has a fifty day simple moving average of $36.87 and a 200 day simple moving average of $32.92. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $92.02 million during the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The firm’s revenue was up 3072.4% compared to the same quarter last year. On average, equities analysts forecast that Liquidia Corporation will post -1.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Wells Fargo & Company upped their price objective on Liquidia from $44.00 to $51.00 and gave the company an “overweight” rating in a research note on Monday, March 23rd. Zacks Research lowered Liquidia from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 27th. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and a consensus price target of $43.44.

Hedge Funds Weigh In On Liquidia

Institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. bought a new position in Liquidia during the fourth quarter valued at $25,000. NewEdge Advisors LLC bought a new stake in shares of Liquidia in the second quarter valued at $25,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia during the 3rd quarter valued at $30,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia during the 3rd quarter valued at $34,000. Finally, Covestor Ltd grew its stake in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).